Department of Head and Neck Surgery & Communication Sciences, Duke University, Durham, North Carolina, U.S.A.
Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina, U.S.A.
Laryngoscope. 2021 Apr;131(4):E1040-E1048. doi: 10.1002/lary.29090. Epub 2020 Sep 22.
Sinonasal squamous cell carcinoma (SCC) is rare with no consensus on treatment regimen. Our goal is to analyze treatment outcomes in poorly differentiated SCC (PDSCC) using a large national database.
Retrospective database study.
The National Cancer Database was queried for sinonasal invasive SCC, grade 3 (poorly differentiated) from 2004 to 2014. Patient demographics and tumor and treatment characteristics were tabulated. Kaplan-Meier (KM) analysis was performed to compare overall survival (OS) between histology subtype and primary site. Multivariable Cox proportional hazards regression was performed for statistical analysis of treatment regimen on OS.
A total of 1,074 patients were identified. The maxillary sinus was the most common site (45%). T4 tumors were observed in 50% of patients, with most patients treated at high-volume facilities (77%). In KM analysis, spindle cell SCC histological subtype, primary tumors of the maxillary sinus, and poorly differentiated grade had worse OS. In our Cox-PH model, higher T stage and age were associated with worse OS. Those treated at a high-volume facility and those who underwent surgical resection followed by adjuvant radiation had improved OS. Chemotherapy within the treatment regimen did not confer survival benefit except in surgical patients when positive margins were present, and surgery with adjuvant chemoradiation trended toward improved survival.
Sinonasal PDSCC appears to be best treated at high-volume centers with surgical resection followed by adjuvant radiation. Poorly differentiated grade has worse OS compared to more differentiated tumors. Chemotherapy along with adjuvant radiation may have a role in patients with positive surgical margins.
4 Laryngoscope, 131:E1040-E1048, 2021.
鼻窦鳞状细胞癌(SCC)较为罕见,其治疗方案尚无共识。我们的目标是利用大型国家数据库分析低分化 SCC(PDSCC)的治疗结果。
回顾性数据库研究。
从 2004 年至 2014 年,国家癌症数据库中检索了鼻窦侵袭性 SCC、3 级(低分化)患者的资料。记录患者的人口统计学、肿瘤和治疗特征。采用 Kaplan-Meier(KM)分析比较组织学亚型和原发部位的总生存率(OS)。采用多变量 Cox 比例风险回归分析对 OS 进行统计学分析。
共纳入 1074 例患者。上颌窦是最常见的部位(45%)。50%的患者存在 T4 期肿瘤,大多数患者在高容量医疗机构接受治疗(77%)。KM 分析显示,梭形细胞 SCC 组织学亚型、上颌窦原发肿瘤和低分化分级与较差的 OS 相关。在我们的 Cox-PH 模型中,较高的 T 分期和年龄与较差的 OS 相关。在高容量医疗机构接受治疗、接受手术切除联合辅助放疗的患者 OS 改善。在治疗方案中,化疗除了在存在阳性切缘的手术患者中具有生存获益外,否则不能带来生存获益,手术联合放化疗有改善生存的趋势。
鼻窦 PDSCC 似乎最好在高容量中心治疗,采用手术切除联合辅助放疗。与分化较好的肿瘤相比,低分化分级的 OS 更差。对于存在手术阳性切缘的患者,化疗联合辅助放疗可能具有一定作用。
4 级 Laryngoscope, 131:E1040-E1048, 2021.